Anales de la RANM

172 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LAS ENFERMEDADES QUE PRODUCE EL CORONAVIRUS José Ramón de Berrazueta Fernández An RANM · Año 2020 · número 137 (02) · páginas 161 a 173 1. Zhong, NS, Zheng BJ, Li YM et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003; 362: 1353–1358. 2. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumo- nia in Saudi Arabia. N. Engl. J. Med. 2012; 367, 1814–1820. 3. Maroto MC, Piédrola G. Los coronavirus. An RANM 2019; 136: 235-238. 4. Tikellis, C, Thomas, MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012; 2012:256294. doi: 10.1155/2012/256294 5. Clerkin KJ, Fried JA, Raikhelkar J et al. CO- VID-19 and Cardiovascular Disease. Circulation 2020; 141: 1648-1655 6. Liu Y, Huang F, Xu J, et al. Anti-hypertensive An- giotensin II receptor blockers associated to mi- tigation of disease severity in elderly COVID-19 patients. medRXiv 2020; published online March 27. DOI:10.1101/2020.03.20.20039586 (preprint). 7. Moore JB, Carl H. June CH. Cytokine release syn- drome in severe COVID-19. Lessons from arthri- tis and cell therapy in cancer patients point to the- rapy for severe diseas. Science 2020; 368:473-474 8. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. A Narrative Review . Ann Intern Med. 2020 Jun 3 : M20-3012. doi: 10.7326/ M20-3012. 9. So L, Smith G. In four U.S. state prisons, nearly 3,300 inmates test positive for coronavirus — 96% without symptoms. Reuters. 25 April 2020. Acces- sed at www.reuters.com/article/us-health-coro- navirus-prisons-testing-in- idUSKCN2270RX. on 26 April 2020. 10. Huang C, Wang Y. Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020; 395: 497-506. 11. Yang X, Yu Y, Xu J et al. Clinical course and out- comes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet 2020. www.thelancet.com/respiratory Published online February 21, 2020 https://doi.org/10.1016/S2213- 2600(20)30079-5) 12. Bénézit F, Le Turnier P, Declerck Ch et al. Uti- lity of hyposmia and hypogeusia for the diag- nosis of COVID-19. Lancet Infect Dis.2020 Published:April 15, 2020. DOI:https://doi. org/10.1016/S1473-3099(20)30297-8 13. Argenziano MG, Bruce SL, Slater Cl et al. Cha- racterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: re- trospective case series. Br Med J 2020;369:m1996. http://dx.doi.org/10.1136/bmj.m1996 14. Berlin DA, Gulick RM, Martínez FJ. Severe Co- vid-19 N Engl J Med 2020. DOI: 10.1056/NE- JMcp2009575. 15. Yang X, Yu Y, Xu J et al. Clinical course and out- comes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet 2020. www.thelancet.com/respiratory Published on- line February 21, 2020 https://doi.org/10.1016/ S2213-2600(20)30079-5. 16. Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the re- nin angiotensin system in health and disease. Int J Pept. 2012:256294. doi: 10.1155/2012/256294. 17. Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003; 58:686– 689. doi: 10.1136/thorax.58.8.686 18. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with CO- VID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054–1062. doi: 10.1016/ S0140-6736(20)30566-3 19. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteris- tics of coronavirus disease 2019 in China [publis- hed online February 28, 2020]. N Engl J Med.2020 doi:.1056/NEJMoa2002032. https://www.nejm. org/doi/full/10.1056/NEJMoa2002032. 20. Huang C,Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5 21. Lala A, Johnson KW, Januzzi JL et al. Prevalence and Impact of Myocardial Injury in Patients Hos- pitalized With COVID-19 Infection.Myocardial Injury in Patients Hospitalized With COVID-19 J Am Coll Cardiol 2020;76: 533–546. 22. Guo T, Fan Y, MD; Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020.doi:10.1001/jamacardio.2020.1017. Published online March 27, 2020. 23. Mancia G, Rea F, Ludergnani M, Apolone G, Co- rrao G. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020;382:2431–2440. 24. Bangalore S, Sharma A, Slotwiner A et al. ST- Segment Elevation in Patients with Covid-19 — A Case Series. N Engl J Med 2020; 382:2478-2480 25. Guagliumi G, Sonzogni A, Pescetelli I, Pel- legrini D, Finn AV. Microthrombi and ST- Segment Elevation Myocardial Infarction in COVID-19. Circulation 2020.10.1161/CIRCULA- TIONAHA.120.049294 26. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wu- han, China. [published online ahead of print, 2020 Mar 3] Intensv Care Med 2020:1–3. https:// doi.org/10.1007/s00134-020-05991-x 27. Peretto G, Sala S, Caforio ALP. Acute myocar- dial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associatedmyo- cardial involvement. Eur Heart J. 2020; 0: 1–2 doi:10.1093/eurheartj/ehaa396 28. Murthy S, Gomersall CD, Fowler RA. Care for cri- tically ill patients with COVID-19. JAMA 2020. March 11 https://doi.org/10.1001/jama.2020.3633 [Epub ahead of print]. 29. Inciardi RM, Lupi L, Zaccone G et al. Car- diac Involvement in a Patient With Coronavi- rus Disease 2019 (COVID-19). JAMA Cardiol. 2020´doi:10.1001/jamacardio.2020.1096 BIBLIOGRAFÍA